Viage Therapeutics, a neuroscience company based on a platform of novel neurotherapeutics, was founded in 2018. The company is based on the ground-breaking research of Dr. Kousaku Ohinata from Kyoto University.
DGX-001, Viage’s clinical drug candidate, represents a first-in-class oral drug candidate targeting the gut-brain axis. The proposed mechanism of action of DGX-001 is to modulate the vagus nerve through specific receptor interactions on enteroendocrine cells in the gut, resulting in a regulation of brain cell activity.
DGX-001 is in clinical development and was well-tolerated in a healthy volunteer Phase 1 study, consistent with its positive safety profile in preclinical GLP studies. In the clinical study, DGX-001 increased specific brain activity (EEG measures) and a post hoc analysis indicated improvements in cognition based on Cogstate tests. Furthermore, human PK measurements have so far been undetectable systemically, confirming the preclinical finding the drug candidate is gut-restricted and gut-acting, which may further minimize off-target side effects as majority of PD patients suffer from comorbidities and polypharmacy.
Viage plans to initiate the Phase 2 program of DGX-001, which initially aims to achieve cognitive improvement across different diseases, representing a transdiagnostic study design, which may ultimately enable indications beyond neurology and psychiatry.
Viage’s pipeline is comprised of both novel neuropeptides and 2nd generation DGX-001-derived peptides and small molecules. It includes SAR-optimized drug candidates with potential in cognitive impairment, depression, anxiety, and inflammatory disease. The drug candidates are gut-acting and gut-restricted, which suggests an advantageous safety profile, particularly compared to most approved psychiatric drugs which suffer from numerous side effects.
The Company is headquartered in the San Francisco Bay Area.
Company Details
- Employees
- 4
- Founded
- -
- Address
- San Francisco, Ca 94123, Us
- Industry
- Biotechnology
- Website
- http://www.viagetx.com
- HQ
- San Francisco, CA
Viage Therapeutics, Inc. Questions
Viage Therapeutics, Inc.'s website is http://www.viagetx.com
Viage Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/viagetx
Viage Therapeutics, Inc. has
4 employees.
View email and phone details for 4
employees at Viage Therapeutics, Inc..
Viage Therapeutics, Inc.'s industry is
Biotechnology
Viage Therapeutics, Inc.'s top competitors are
An Venture Partners,
Capacity Bio,
Sardocor,
Endurance Bio Inc.,
Typewriter Therapeutics, Inc.,
Solid Biosciences,
Shanghai Allist Pharmaceuticals Co., Ltd,
Medilink Therapeutics,
Entheos Labs,
Anri.
Viage Therapeutics, Inc.'s categories are Biotechnology
Viage Therapeutics, Inc.'s founding year is 2018
